ACC BioRepository

ACC生物样本库

• 批准号: 10088758
• 负责人: MICHAEL D FELDMAN
• 金额: --
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-15 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10088758
• 关键词: Address; Air Conditioning; Basic Science; Biological Specimen Banks; Biological Specimen database; Biopsy; Biopsy Specimen; Blood; Blood specimen; Cancer Center; Cancer Center Support Grant; Cell Survival; Cells; Clinical Data; Clinical Investigator; Clinical Pathology; Clinical Protocols; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Collection; Consent; Consultations; Coupled; DNA; Data; Development; Disease; Electronic Health Record; Ensure; Equipment and supply inventories; Excision; Farming environment; Freezing; Genotype; Home; Hospitals; Human; Image Guided Biopsy; Immunosuppression; Industry; Interventional radiology; Laboratories; Lead; Link; Location; Malignant Neoplasms; Medicine; Mission; Monitor; Nature; Neoplasm Circulating Cells; Normal tissue morphology; Operative Surgical Procedures; Outcome; Pathologic; Pathology; Patients; Pennsylvania; Plasma; Population; Population Sciences; Precancerous Conditions; Procedures; Process; Proteins; Protocols documentation; Pumpkins; Radiology Specialty; Reporting; Research; Research Personnel; Resource Sharing; Resources; Review Committee; Sampling; Security; Serum; Services; Side; Specimen; System; Time; Tissue Banks; Tissue Sample; Tissues; Translational Research; Tumor Tissue; University Hospitals; Utilization Review; Work; biobank; blood product; cancer imaging; cancer surgery; clinical care; cohort; cost effectiveness; data registry; exome; exome sequencing; exosome; extracellular vesicles; genomic data; informatics infrastructure; interest; liquid biopsy; medical schools; member; programmed cell death ligand 1; programs; prospective; radiologist; remote monitoring; repository; sample archive; sample collection; sensor; tumor; tumor DNA; tumor registry; vapor

PROJECT SUMMARY – Abramson Cancer Center BioRepository (ABR) The Abramson Cancer Center BioRepository (ABR) is a shared core laboratory comprised of four integrated components that together enable the collection of tumor and normal tissue samples from surgical resections and radiology guided biopsy (supporting clinical trials), blood collections (buffy coats, serum and plasma), and liquid biopsy (ctDNA, CTC, soluble proteins and extra-cellular vesicles). This integrated Shared Resource leverages uniformity of quality across a breadth of biosamples and enhanced efficiencies gained through use of a universal consent. The tumor tissue, blood collection and liquid biopsy material collections are supported by a new prospective universal consent allowing for collection of blood and tissue (at time of surgery), patient re-contact, “omics” study of the collected biosamples, and linkage to electronic health records for outcome- related translational research. Biosample inventory data are managed through Open Specimen, a commercial biosample database on the tissue side, and Pumpkin, a home-grown system for blood sample processing – both well-suited to handle large volume sample collections and archiving. Penn Medicine has a centralized informatics infrastructure (PennOmics v2) composed of an enterprise DataLake that combines EHR data, tumor registry data, and genomic data (germline and somatic studies) that links to stored biosample inventories across our biosample database (Open Specimen and Pumpkin) that allows for cohort exploration and requesting biosamples from these cohorts. Biosamples are stored in two new freezer farms recently constructed at the Perelman School of Medicine in either -80 freezers (buffy coats, plasma and serum) or LN2 vapor (tissue or viable cells). Both freezer farms have completely redundant air conditioning, electric and central monitoring resources including remote monitoring and alarms with O2 security sensors to support LN2 vapor storage. ABR is tightly coupled with a larger institutional biosample repository (Penn Medicine Biobank) which has grown to >60K patient blood samples, including whole exome sequencing and genotyping on >15K of these patients. The Penn Medicine Biobank is a broad effort across Penn Medicine that seeks to collect blood and tissues across a wide range of both normal patients as well as patients with a variety of diseases. The ABR Shared Resource is directed by Dr. Michael Feldman, who has been leading the tumor tissue and blood repository since its inception in 2005. Ms. Joellen Weaver, Technical Director, has worked in biobanking for 20 years. ACC members accounted for 43 of 62 investigators (69%) using this Shared Resource during the most recent reporting period (07/01/18-06/30/19). ABR has supported high-impact research, e.g. changing the fundamental understanding of immune suppression in tumors via PDL1-carrying exosomes (Chen et al., Nature, 2018). ABR facilitates access to a wide variety and number of biospecimens for ACC members across the basic, clinical, and population science Programs, addressing the changing scientific needs of ACC membership and increased research demand for tissue and blood products.

项目总结- Abramson癌症中心生物库（ABR） Abramson癌症中心BioRepository（ABR）是一个共享的核心实验室，由四个综合实验室组成。 这些组件一起能够从手术切除中收集肿瘤和正常组织样本 和放射学引导活检（支持临床试验），血液采集（血沉棕黄层，血清和血浆），以及 液体活检（ctDNA、CTC、可溶性蛋白和细胞外囊泡）。此集成共享资源 利用生物样本的质量一致性，并通过使用提高效率 一个普遍的同意。支持肿瘤组织、血液采集和液体活检材料采集 通过允许采集血液和组织（手术时）的新的前瞻性普遍同意，患者 重新接触，对收集的生物样本进行“组学”研究，并与电子健康记录联系，以获得结果- 相关的翻译研究。生物样本库存数据通过Open Specimen进行管理， 组织方面的生物样本数据库，以及Pumpkin，一种用于血液样本处理的自制系统- 两者都非常适合处理大量样品收集和存档。宾夕法尼亚大学医学中心有一个 信息学基础设施（PennOmics v2）由企业DataLake组成， 肿瘤登记数据和基因组数据（生殖系和体细胞研究），与储存的生物样本库存相关联 在我们的生物样本数据库（Open Specimen和Pumpkin）中，允许进行队列探索， 要求从这些群体中提取生物样本生物样本最近储存在两个新的冷冻农场 在Perelman医学院构建，在-80冰柜（血沉棕黄层，血浆和血清）或液氮2中 蒸汽（组织或活细胞）。两个冷冻农场都有完全多余的空调，电力和 中央监控资源，包括远程监控和报警，带有O2安全传感器，以支持LN 2 蒸汽储存ABR与更大的机构生物样本库（Penn Medicine Biobank）紧密结合 已经增长到超过60 K患者血液样本，包括全外显子组测序和基因分型> 15 K 这些病人。宾州医学生物库是宾州医学界的一项广泛努力，旨在收集 在正常患者以及患有多种疾病的患者的广泛范围内的血液和组织中。 ABR共享资源由Michael Feldman博士指导，他一直领导肿瘤组织和 自2005年成立以来，血液储存库。Joellen Weaver女士，技术总监，曾在生物库工作 20年ACC成员占62名研究者中的43名（69%），在研究期间使用了该共享资源。 最近报告期（2018年1月7日至2019年6月30日）。ABR支持高影响力的研究，例如改变 通过携带PDL 1的外来体对肿瘤中免疫抑制的基本理解（Chen等， Nature，2018）。ABR为ACC成员提供了多种多样的生物标本， 基础，临床和人口科学计划，解决ACC不断变化的科学需求 会员资格和对组织和血液制品的研究需求增加。